insights_auto
Why is 524494 down 3,51%?
Dive Deeperchevron_right
524494:BOM
IPCA Laboratories Ltd
₹1 845,00
arrow_downward
-3,51%(-67,20) 1D
16 Okt., 15:30:00 GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 524494...
Open
₹1 913,95
High
₹1 913,95
Low
₹1 812,60
Mkt. cap
468,21 mjd
Avg. vol.
27,90 k
Volume
12,00 k
Dividend
0,33%
Quarterly dividend
₹1,50
Ex-dividend date
07 Aug. 2026
P/E ratio
35,74
52-wk high
₹2 039,30
52-wk low
₹1 252,95
EPS
₹51,63
Shares outstanding
126,35 m
No. of employees
17 k
Open
₹1 913,95
High
₹1 913,95
Low
₹1 812,60
Mkt. cap
468,21 mjd
Avg. vol.
27,90 k
Volume
12,00 k
Dividend
0,33%
Quarterly dividend
₹1,50
Ex-dividend date
07 Aug. 2026
P/E ratio
35,74
52-wk high
₹2 039,30
52-wk low
₹1 252,95
EPS
₹51,63
Shares outstanding
126,35 m
No. of employees
17 k
News stories
From web sources and news partners
Quiver Quantitative
·
23 minute gelede
Private Bancorp of America Reports Third Quarter 2026 Net Income of $11.4 Million and Diluted EPS of $1.97 as Deposits and Loans Grow After NASDAQ Uplisting
The Daily News | Texas' Oldest Newspaper
·
33 minute gelede
FILE PHOTO: Signage is seen outside the New York Stock Exchange (NYSE) in Manhattan, New York City
MarketWatch
·
1 uur gelede
Nearly 40% of the S&P 500 is in a bear market. Here are 10 of those stocks that analysts say can gain up to 81%.
Fort Worth Star-Telegram
·
1 uur gelede
Wall St futures mixed as tech wobbles again, Tesla gains
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd